| Basal insulin and cardiovascular and other outcomes in dysglycemia OT Investigators New England Journal of Medicine 367 (4), 319-328, 2012 | 2013 | 2012 |
| Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) JB Buse, J Rosenstock, G Sesti, WE Schmidt, E Montanya, JH Brett, ... The Lancet 374 (9683), 39-47, 2009 | 1944 | 2009 |
| Cardiovascular efficacy and safety of bococizumab in high-risk patients SCO Investigators New England Journal of Medicine 376 (16), 1527-1539, 2017 | 1759* | 2017 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial The Lancet 292 (10157), 1519-1529, 2018 | 1335* | 2018 |
| N-3 fatty acids and cardiovascular outcomes in patients with dysglycemia OT Investigators New England Journal of Medicine 367 (4), 309-318, 2012 | 1097 | 2012 |
| Defects of the insulin receptor substrate (IRS) system in human metabolic disorders G Sesti, M Federici, ML Hribal, D Lauro, P Sbraccia, R Lauro The FASEB Journal 15 (12), 2099-2111, 2001 | 501 | 2001 |
| Pathophysiology of insulin resistance G Sesti Best practice & research Clinical endocrinology & metabolism 20 (4), 665-679, 2006 | 497 | 2006 |
| High glucose causes apoptosis in cultured human pancreatic islets of Langerhans: a potential role for regulation of specific Bcl family genes toward an apoptotic cell death program M Federici, M Hribal, L Perego, M Ranalli, Z Caradonna, C Perego, ... Diabetes 50 (6), 1290-1301, 2001 | 487 | 2001 |
| Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells M Federici, R Menghini, A Mauriello, ML Hribal, F Ferrelli, D Lauro, ... Circulation 106 (4), 466-472, 2002 | 453 | 2002 |
| Uric acid and endothelial dysfunction in essential hypertension C Zoccali, R Maio, F Mallamaci, G Sesti, F Perticone Journal of the American Society of Nephrology 17 (5), 1466-1471, 2006 | 374 | 2006 |
| Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension F Perticone, A Sciacqua, R Maio, M Perticone, R Maas, RH Boger, ... Journal of the American College of Cardiology 46 (3), 518-523, 2005 | 361 | 2005 |
| Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin … O Vaccaro, M Masulli, A Nicolucci, E Bonora, S Del Prato, AP Maggioni, ... The lancet Diabetes & endocrinology 5 (11), 887-897, 2017 | 274 | 2017 |
| Angiotensin II impairs the insulin signaling pathway promoting production of nitric oxide by inducing phosphorylation of insulin receptor substrate-1 on Ser312 and Ser616 in … F Andreozzi, E Laratta, A Sciacqua, F Perticone, G Sesti Circulation research 94 (9), 1211-1218, 2004 | 266 | 2004 |
| Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome … BJ Origin Trial Investigators, Gerstein H, Yusuf S, Riddle MC, Ryden L Am Heart J 155 (1), 26-32, 2008 | 252 | 2008 |
| Pulse pressure and endothelial dysfunction in never-treated hypertensive patients R Ceravolo, R Maio, A Pujia, A Sciacqua, G Ventura, MC Costa, G Sesti, ... Journal of the American College of Cardiology 41 (10), 1753-1758, 2003 | 248 | 2003 |
| Insulin receptor substrate (IRS) transduction system: distinct and overlapping signaling potential B Giovannone, M Lucia Scaldaferri, M Federici, O Porzio, D Lauro, ... Diabetes/metabolism research and reviews 16 (6), 434-441, 2000 | 227 | 2000 |
| Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents JB Buse, G Sesti, WE Schmidt, E Montanya, CT Chang, Y Xu, L Blonde, ... Diabetes care 33 (6), 1300-1303, 2010 | 215 | 2010 |
| The Gly972→Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β cells O Porzio, M Federici, ML Hribal, D Lauro, D Accili, R Lauro, P Borboni, ... The Journal of clinical investigation 104 (3), 357-364, 1999 | 214 | 1999 |
| A phase 2, randomized, dose-finding study of the novel once-weekly human GLP-1 analog, semaglutide, compared with placebo and open-label liraglutide in patients with type 2 … MA Nauck, JR Petrie, G Sesti, E Mannucci, JP Courreges, ML Lindegaard, ... Diabetes care 39 (2), 231-241, 2016 | 213 | 2016 |
| Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals E Succurro, MA Marini, S Frontoni, ML Hribal, F Andreozzi, R Lauro, ... Obesity 16 (8), 1881-1886, 2008 | 212 | 2008 |
Francesco PerticoneFull Professor of Internal Medicine, University Magna Graecia of Catanzaro, ItalyBestätigte E-Mail-Adresse bei unicz.it
